Benefits persist in T cell therapy for children with relapsed leukemia

An innovative therapy against a highly aggressive leukemia continues to show highly promising results in children treated in a pilot study. Of 39 children receiving bioengineered T cells, 92 percent had no evidence of cancer a month after treatment.